QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI Case Intake, Triage and Initial Assessment

Test your understanding of the concepts covered by GVP Module VI: Case Intake, Triage and Initial Assessment.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Two communications describe the same patient and reaction, but the second source provides additional clinical details. What should happen?

Discard the second communication because the first report already exists. Create an unrelated new case automatically. Route the communication for duplicate assessment and incorporate relevant information into the appropriate case structure. Retain only the second communication because it came from a healthcare professional.

Question 2 of 10 Why should initial capture generally occur before complete classification of a potentially relevant communication?

Because every communication must automatically become a valid ICSR. Because preserving the original information prevents incompleteness from causing premature loss or suppression of potentially relevant safety information. Because classification is never required in the intake process. Because database entry always establishes the regulatory Day 0.

Question 3 of 10 What should a controlled handoff from intake to case processing establish?

Only the proposed case priority and database user. Source, awareness date, product, patient and reporter information, event details, preliminary seriousness indicators, duplicate status and escalations. Only the final causality and expectedness assessment. The submission outcome, even if validation has not yet occurred.

Question 4 of 10 A patient-support programme systematically collects adverse-event information from patients. How should the intake process treat the source?

Automatically classify every report as spontaneous because the patient provided the information. Preserve the patient-support-programme context because source classification affects subsequent processing and reporting pathways. Exclude the information from PV because it was collected through a programme. Classify it as a clinical-trial report unless a physician submitted it.

Question 5 of 10 Which set of characteristics most closely reflects the qualities expected of collected safety information?

Authentic, legible, accurate, consistent, verifiable and as complete as possible for clinical assessment. Concise, commercially favourable, fully classified and limited to database fields. Anonymous, abbreviated, unverified and entered only after medical review. Uniformly serious, causally related, expected and submission-ready.

Question 6 of 10 An affiliate receives a potentially serious report several days before central PV receives it. What is the most appropriate organisational response?

Use the central database-entry date because that is the only date visible to PV. Ignore the affiliate receipt date because affiliates are outside the central PV organisation. Reconstruct the information pathway, determine the applicable awareness date, assess timeline impact and review whether similar transfers were affected. Delete the affiliate record to avoid conflicting dates.

Question 7 of 10 A notification says, 'The patient died while taking Product X.' What is the most appropriate intake interpretation?

The cause of death is established as an adverse reaction to Product X. The report should be ignored because death is an outcome rather than an event. The information should be preserved and appropriately escalated without inventing a cause of death or adverse reaction. The report should be coded as non-serious until a death certificate is received.

Question 8 of 10 How should special situations such as medication error, overdose or pregnancy exposure be handled at intake?

They should bypass standard capture and validation because they are not ordinary spontaneous reports. They should be captured and assessed through standard intake and validation controls, followed by the relevant specialised workflow. They should automatically be classified as serious cases. They should be excluded unless an adverse reaction is already confirmed.

Question 9 of 10 Why should an organisation test both source-to-case and case-to-source traceability?

Because only database records are relevant to inspections. Because the two directions assess different risks: missed capture from source systems and the ability to reconstruct the origin and handling of existing cases. Because source-to-case testing replaces validation and case-to-source testing replaces medical review. Because both tests are needed only when a vendor is involved.

Question 10 of 10 A product complaint includes information that a patient experienced a severe reaction after administration. Which process design is most appropriate?

Allow the quality function to decide whether PV assessment is necessary. Allow PV to ignore the complaint because quality owns the source communication. Connect quality and PV workflows so the complaint can be investigated while the clinical information is independently assessed for PV relevance. Create only a quality record because one communication cannot support two processes.

QPPV.com

Knowledge Assessment: GVP Module VI Case Intake, Triage and Initial Assessment

Cookie Settings